Skip to content

SAB Pharma

Active Private limited companyfounded 2018active for 8 yearsRue de Gourgues 21, 7608 PéruwelzKBO/BCE: BE 0687.692.485

Lifetime

8 annual accounts with figures on one time axis
peak of €101,341 in 2022
€38,513▲ 42.3%
lowest -€20,450 in 2021
€19,532▲ 93.3%
peak of €104,068 in 2023
€29,522▼ 1.6%
€76,613▼ 34.7%
Board2 names since 2018
1 director
Documentsfilings and deeds
26-08-202626 days late
2025micro format
Gross margin from €27,063 to €38,513Result from €10,102 to €19,532Dividend €20,000Debts from €117,262 to €76,613Investments €23,347Cash from €20,530 to €27,493

Key points

from the 2025 annual accounts

Equity

€29,522 from €104,068 in 2023

Equity fell by 72% in 2 years.

Debts

€76,613 72% of the balance sheet
Financial debts 14%Suppliers 3%Taxes and wages 15%Other 68%

Of this, €65,861 falls due within a year.

Filings

8 annual accounts 8 late
AprilJune31 JulyOctober20202025

The 2020 accounts came in latest, 135 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,715 companies had the same profile as SAB Pharma has now. Each dot stands for 17 companies, two years later.

95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,715 companies, not a prediction for SAB Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
  • 93 sharesdeed of 11-01-2018
  • 93 sharesdeed of 11-01-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0687692485
Registered office moved from WIERS Rue de Gourgues to Péruwelz The registered office moved from 21, 7608 WIERS Rue de Gourgues to rue de Gourgues 21, 7608 Péruwelz · resigns as manager · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 13-09-2019 · Gazette deed
Registered office moved from UCCLE Rue du Roetaert to WIERS Rue de Gourgues The registered office moved from 1180 UCCLE Rue du Roetaert 144 boite 7 to 21, 7608 WIERS Rue de Gourgues · Gazette deed
Registered office moved from UCCLE Chaussée d'Alsemberg to UCCLE Rue du Roetaert The registered office moved from 515, 1180 UCCLE Chaussée d'Alsemberg to 144 boîte 7, 1180 UCCLE Rue du Roetaert · General meeting of 12-04-2018 · Gazette deed
All 18 events

Comparable companies

same main activity, similar in size and age
Company
SAB Pharma Péruwelz €106,135 €38,513 27.8% -
APEGO Geel €89,749 €36,274 65.9% -
MEDLINX LINA Schaerbeek €130,245 €42,645 16.9% -
PHARDEP Ottignies-Louvain-la-Neuve €117,517 €29,630 50.0% -
TRAVEL PHARMA Oudenaarde €90,536 €41,397 -10.9% -
Van Meirhaeghe Katrien Herzele €84,640 €34,286 12.1% -
CURASAN Zwalm €103,974 €43,839 87.5% -

These companies have the same main activity as SAB Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €84,600 and €130,000, founded between 2015 and 2020.

Official details

Source: KBO
Status
Active since 09-01-2018Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.273.346.4387608 Péruwelz, registered on 09-01-2018
Financial year end
31 December
Peppol
Reachable since 12-12-2025
Company details

Annual accounts 2025

≈ €180,000estimated
€106,135▼ 27.9%
Filing
Filed on 26-08-2026
Financials

Insights on SAB Pharma

SAB Pharma files the micro format. That format states no turnover. The gross margin fell from €38,866 in 2018 to €38,513 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about SAB Pharma

What is the company number of SAB Pharma?
The company number of SAB Pharma is 0687.692.485. The VAT number is the same number with BE in front: BE 0687.692.485.
Where is SAB Pharma based?
The registered office is at Rue de Gourgues 21, 7608 Péruwelz.Company details
What does SAB Pharma do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of SAB Pharma?
SAB Pharma is a private limited company (BV).
When was SAB Pharma founded?
SAB Pharma was founded on 09-01-2018.
Is SAB Pharma still active?
Yes, SAB Pharma is an active enterprise in the KBO register.
What is the turnover of SAB Pharma?
The turnover in financial year 2025 is ≈ €180,000. This figure is estimated from the gross margin of €38,513 and 56 comparable companies (NACE 477). It probably lies between €97,000 and €320,000.Financials
Is SAB Pharma profitable?
In financial year 2025, SAB Pharma made a profit of €19,532.
Where can I find the annual accounts of SAB Pharma?
SAB Pharma filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of SAB Pharma due?
SAB Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.